The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Investigators Initiate Post-Trastuzumab Trial of GLSI-100 in Patients With Invasive Breast Cancer

December 7th 2021, 6:09pm


Investigators hope to duplicate promising phase 2b trial results with an experimental peptide vaccine in a population of nearly 500 patients with human epidermal growth factor receptor 2 breast cancer.

Field of Potential Adalimumab Biosimilar Contenders Continues to Grow

December 2nd 2021, 2:30pm


The list of potential adalimumab biosimilars has now lengthened to 10, according to a Cardinal Health summary of these products and their distinguishing features.

Proponents of Uniform Billing Codes for Biosimilars Cite Generic Savings Success

November 30th 2021, 8:56pm


Generics and biosimilars are reimbursed differently, causing providers to prefer lower-cost generics and higher-priced biologics, authors of a study and opinion piece contend.

AMCP Nexus Survey: Two-Thirds of Payers Use Biosimilars to Manage Oncology Drug Costs

November 23rd 2021, 4:00pm


As the cost of oncology drugs increases, there has been a growing pressure to manage oncology drug spend, which some payers have done by establishing preferred therapies, including biosimilars.

EMA and WHO "Tailor" the Biosimilar Development Process

November 23rd 2021, 12:07pm


The European Medicines Agency (EMA) reports on progress to create a smoother, less wasteful biosimilar development process; and the World Health Organization (WHO) revises its biosimilar development guidelines.

AAM Panel of Manufacturers Says Drug Price Rebates Must Go

November 16th 2021, 10:05pm


Sandoz, Lupin, and Biocon Biologics representatives at the Association for Accessible Medicines (AAM) GRx+Biosims conference said that drug price rebates hinder biosimilar competition.

Evaluating Biosimilar Programs and Formularies

November 16th 2021, 5:38pm


Kathy Oubre, MS, closes this Insights program by evaluating her organization’s biosimilars program and formularies, including third party preference on the use of specific biosimilars and whether biosimilars can be used outside of their indications.

Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care Plans

November 16th 2021, 5:33pm


Two experts explain if they had to create any incentives for health care providers to prescribe biosimilars, whether they encountered challenges with their electronic health records, and if their biosimilar programs impacted their clinical pathway/care plans.

COA Reports Improved Biosimilar Access in Oncology

November 15th 2021, 4:15pm


For trastuzumab and bevacizumab, biosimilars now represent a high share of administrations, but payer policies still hinder uptake of these products, the Community Oncology Alliance (COA) reports.

Biosimilar Interchangeability: What's in a Name?

November 11th 2021, 12:00pm


There is now a mad scramble to gain interchangeable status for biosimilars, but the meaning and significance of this appellation haven't yet been worked out for health care consumers or the manufacturing community.